Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

A parliamentary committee in Canada has recommended that the country's assisted dying laws continue to exclude people whose sole underlying condition is a mental illness.

According to the committee's report, Canada's assisted dying framework should "indefinitely exclude" individuals whose only medical condition is a mental illness.

Canada first passed its assisted dying legislation, known as Bill C-14, in 2016, marking a significant development in healthcare and personal autonomy.

Officially known as Medical Assistance in Dying (MAID), the law initially applied only to adults who were terminally ill. However, eligibility for MAID has remained one of the country's most contentious healthcare issues over the past decade, with plans to expand access delayed twice.

Committee Recommends Permanent Exclusion

The 98-page report by the joint House and Senate committee on Medical Assistance in Dying contains a single recommendation: that Canada "indefinitely exclude persons whose sole underlying medical condition is a mental illness from eligibility for medical assistance in dying", according to the BBC.

The report noted a "divergence of perspectives" on the issue and highlighted concerns raised during testimony about the "pressing need for increased and more equitable access to adequate mental health services".

However, some committee members disagreed with the findings and published a dissenting report, arguing that the process was "fundamentally flawed", "biased", and favored testimony from those opposed to expanding MAID. Canada's government must respond to the report by July 11.

Also read: Noelia Castillo: 25-year-old Spanish Woman Dies By Euthanasia After Long Legal Battle

What Does Canada's MAID Law Say?

When MAID was introduced in 2016, it was available only to adults who were terminally ill.

The eligibility criteria were strict. Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".

This legal pathway became known as Track 1. Modelled on end-of-life care, it primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process. Track 1 remains a relatively swift procedure, with some patients receiving MAID within a day of applying.

Expansion Beyond Terminal Illness

Read More: Passive Euthanasia: Harish Rana’s Case May Reshape End-of-life Protocols, Say Experts

However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.

In 2019, the country introduced Bill C-7 in 2021, creating Track 2 and extending MAID eligibility to people with serious, incurable conditions causing enduring suffering even when death was not foreseeable.

Track 2 includes additional safeguards, including a 90-day assessment period, evaluation by two independent clinicians, and consultation with specialists when necessary.

Ongoing Debate Over Mental Illness Eligibility

Despite its stricter safeguards and ethical complexities, Track 2 MAID has steadily gained use. In 2023, there were 622 deaths under Track 2 compared with 14,721 under Track 1.

Supporters view Track 2 as a compassionate option for people living with severe, non-terminal suffering, while critics argue it risks exposing vulnerable populations to premature death.

In 2023, Canada first delayed eligibility for MAID for people whose sole condition was a mental illness by one year, citing concerns that the healthcare system was not ready for the expansion. The government later delayed implementation again until March 17, 2027.

Along with the second delay, the government recommended that a parliamentary committee undertake a comprehensive review of the proposal.

MAID Accounts For About 5% of Deaths in Canada

According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.

The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".

The United States is witnessing a rise in cases of Powassan virus disease, a rare but potentially deadly illness transmitted through tick bites. Unlike many other tick-borne diseases, Powassan virus can be transmitted within 15 minutes of a tick attaching to the skin, making prevention and awareness especially important.

According to the US Centers for Disease Control and Prevention (CDC), tick exposure can occur throughout the year, although ticks are most active during the warmer months between April and September.

Emergency physician Dr. Rick Pescatore recently highlighted the growing threat in a TikTok video post, warning that many people remain unaware of the virus despite its severe health consequences.

"There's a new and deadly tick virus that's spreading across the United States, and you probably haven't heard about it," he said.

Pescatore emphasized the seriousness of the infection, noting that "about one in 10 people with severe disease die, while around half of survivors may experience permanent neurological damage". He also claimed that reported cases have increased steadily over the past decade.

Several state health departments have urged residents to take precautions after reporting cases of the rare disease.

In one recent case, a 66-year-old man from New Hampshire was hospitalized for several weeks after contracting the virus. After initially being admitted to Concord Hospital, he was later transferred to Massachusetts General Hospital for specialized care.

What Is Powassan Virus?

Also read: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant

The Powassan virus is named after the town of Powassan in Ontario, Canada, where it was first identified in 1958. It belongs to the flavivirus family, which also includes viruses that cause Zika, dengue, and West Nile fever.

The virus is primarily spread by the black-legged tick (Ixodes scapularis), also known as the deer tick, which is also responsible for transmitting Lyme disease.

However, unlike Lyme disease—which generally requires a tick to remain attached for more than 24 hours before transmission—Powassan virus can be transmitted in as little as 15 minutes, according to the Massachusetts Department of Public Health.

Symptoms of Powassan Virus Infection

Read More: South Korea Achieves 62% Blood Pressure Control Rate: What Other Countries Can Learn

Symptoms typically develop between seven and 30 days after a tick bite and may include:

• Fever
• Headache
• Vomiting
• Weakness
• Confusion
• Loss of coordination
• Seizures
• Difficulty speaking

These complications can lead to long-term neurological damage. According to Yale Medicine, approximately 10 per cent of severe cases are fatal, while nearly 50 per cent of survivors experience lasting neurological problems.

No Vaccine or Treatment Available

One of the most concerning aspects of the Powassan virus is that there is currently no vaccine or antiviral treatment available.

Unlike Lyme disease, which can be treated with antibiotics, Powassan virus has no specific cure. Medical care focuses on managing symptoms and supporting patients with severe disease.

As a result, prevention remains the most effective defense against infection.

How to Prevent Tick Bites

The CDC and the National Institutes of Health (NIH) recommend the following measures to reduce the risk of tick bites:

• Wear long-sleeved shirts and long pants when outdoors
• Choose light-colored clothing to make ticks easier to spot
• Tuck pants into socks or seal gaps in clothing
• Use insect repellents containing DEET, picaridin, or permethrin
• Stay in the center of hiking trails and avoid brushing against vegetation
• Check your body, clothing, pets, and outdoor gear for ticks after spending time outside
• Shower and wash clothing in hot water soon after returning indoors

If you find a tick attached to your skin, remove it promptly using fine-tipped tweezers.

Amid the ongoing Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC), the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus diseases, a group that includes all Ebola and Marburg virus infections.

Ebola and Marburg diseases are severe, often fatal illnesses that have caused repeated outbreaks across Africa. Since the discovery of the Marburg virus in 1967, there have been 72 documented outbreaks of Ebola and Marburg diseases.

There are currently no licensed vaccines and treatments for Marburg virus disease, as well as Bundibugyo and Sudan virus diseases. Thus, the WHO emphasized that early supportive care remains one of the most effective ways to improve survival.

"The current Bundibugyo virus outbreak is a stark reminder of the need for diligent, holistic and person-focused medical care to save lives and preserve human dignity. We encourage governments and authorities to integrate these new recommendations into preparedness and outbreak response to ensure high-quality care for everyone," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

Also read: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations

What Do The New Guidelines Recommend?

The WHO has previously published disease-specific guidance on Ebola care and therapeutics. However, the newly released guidelines are the first to provide a comprehensive framework covering all filovirus diseases, including Ebola and Marburg.

Developed through consultations with global experts and based on the latest scientific evidence, the guidelines contain 16 evidence-based recommendations focused on improving supportive care and reducing mortality.

The recommendations are designed to help frontline healthcare workers:

• Identify clinical deterioration early
• Manage dehydration and shock effectively
• Improve patient monitoring
• Deliver critical supportive interventions safely
• Provide structured follow-up care for survivors

Key Recommendations include:

• Prioritizing Laboratory Testing
• Rapid Treatment of Dehydration
• Early Management of Shock
• Treatment should be guided by continuous monitoring of vital signs and indicators of tissue perfusion.
• Treat Secondary Bacterial Infections
• Provide Long-Term Follow-Up Care

The WHO also recommended structured after-care programs for survivors to support recovery, improve long-term well-being, and reduce the risk of infections linked to viral persistence after recovery.

Supportive Care Remains Critical

For Bundibugyo virus disease and other filovirus infections, WHO stressed that early recognition, rapid referral, and optimized supportive care remain the foundation of patient management.

Effective supportive care can reduce complications, improve survival, and provide the basis for evaluating potential antiviral treatments through future clinical research.

Ebola Outbreak Faced Major Contact-Tracing Gaps

Meanwhile, the Africa Centers for Disease Control and Prevention (Africa CDC) has raised concerns about significant weaknesses in contact-tracing efforts during the ongoing outbreak.

According to Africa CDC Director-General Dr. Jean Kaseya, more than 28,000 people who have been in contact with confirmed Ebola patients are currently not being monitored.

Responders should be tracking approximately 33,080 contacts, but only 4,112 are being actively followed, he said during a high-level meeting.

The agency warned that the outbreak is spreading at a pace that surveillance systems are struggling to keep up with.

Read More: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

Ebola: More Than 800 Confirmed Cases

As per latest update till June 15, there are 827 confirmed Ebola cases linked to the outbreak in the Congo and 196 confirmed death.

Health officials estimate that each infected person may have come into contact with around 40 other individuals, creating a large pool of people at risk of infection.

Because Ebola can take up to 21 days for symptoms to appear, all identified contacts should ideally be monitored throughout the incubation period.

Africa CDC officials cautioned that without stronger surveillance and contact-tracing efforts, controlling the outbreak will become increasingly difficult, despite advances in clinical care and patient management.